New siRNA drug aims to halt liver damage in NASH patients
NCT ID NCT06322628
First seen Mar 16, 2026 · Last updated May 24, 2026 · Updated 11 times
Summary
This study tests an experimental drug called VSA006 in 48 Chinese adults with NASH, a type of fatty liver disease that can lead to scarring. The drug works by targeting a gene linked to liver protection. Researchers want to see if it can improve liver health and reduce fat without making the disease worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASH are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing Tsinghua Changgeng Hospital
Beijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.